Product Center
Obtained Clinical Trial Approval for a Novel First-in-Class Biologic
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-11-11
- Views:
(Summary description)In 2017, the company used its own patented technology to develop a first-class biological product: the quadrivalent influenza virus subunit vaccine, which was approved by the CFDA (now NMPA) for clinical trials.
Obtained Clinical Trial Approval for a Novel First-in-Class Biologic
(Summary description)In 2017, the company used its own patented technology to develop a first-class biological product: the quadrivalent influenza virus subunit vaccine, which was approved by the CFDA (now NMPA) for clinical trials.
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-11-11 10:57
- Views:
In 2017, the company used its own patented technology to develop a first-class biological product: the quadrivalent influenza virus subunit vaccine, which was approved by the CFDA (now NMPA) for clinical trials.
Relevant information
-
The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States.Recently, the IND application for a Class 1 new drug, the "Monkeypox mRNA vaccine," jointly submitted by Ab&B Bio-Tech CO.,LTD.JS (Ab&B Bio) and its subsidiary Yither Biotech CO., Ltd (Yither Bio), was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration. - Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched 05-13
- The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
